Brockbank J, Krause T, Moss E, Pedersen AM, Morup MF, Ahdesmaki O, Vaughan J, Brodtkorb T-H. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes. 2021 Mar 18;19(1):94. doi: 10.1186/s12955-021-01723-x
Doherty K, Marcano-Belisario J, Cohn M, Mastellos N, Morrison C, Car J, Doherty G. Engagement with mental health screening on mobile devices: results from an antenatal feasibility study. Poster presented at the 2019 CHI Conference on Human Factors in Computing Systems; May 2019. Glasgow, Scotland. doi: 10.1145/3290605.3300416
Doherty K, Barry M, Marcano-Belisario J, Arnaud B, Morrison C, Car J, Doherty G. A mobile app for the self-report of psychological well-being during pregnancy (BrightSelf): qualitative design study. JMIR Ment Health. 2018 Nov 27;5(4):e10007. doi: 10.2196/10007
Imagawa H, Nagar SP, Montgomery W, Nakamura T, Sato M, Davis KL. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatr Dis Treat. 2018 Feb 22;14:611-21. doi: 10.2147/NDT.S150261
Marcano Belisario JS, Doherty K, O'Donoghue J, Ramchandani P, Majeed A, Doherty G, Morrison C, Car J. A bespoke mobile application for the longitudinal assessment of depression and mood during pregnancy: protocol of a feasibility study. BMJ Open. 2017 May 29;7(5):e014469. doi: 10.1136/bmjopen-2016-014469
Marcano-Belisario JS, Gupta AK, O'Donoghue J, Ramchandani P, Morrison C, Car J. Implementation of depression screening in antenatal clinics through tablet computers: results of a feasibility study. BMC Med Inform Decis Mak. 2017 May 10;17(1):59. doi: 10.1186/s12911-017-0459-8
Barry M, Doherty K, Marcano-Belisario J, Car J, Morrison C, Doherty G. mHealth for maternal mental health: everyday wisdom in ethical design. Poster presented at the 2017 CHI Conference on Human Factors in Computing Systems; May 2017. Denver, CO.
Nagar SP, Sato M, Montgomery W, Nakamura T, Imagawa H, Davis KL. Treatment patterns and characteristics of adult patients with attention deficit/hyperactivity disorder receiving atomoxetine in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A305.
Wilkinson A, Anderson S, Wheeler SB. Screening for and treating postpartum depression and psychosis: a cost-effectiveness analysis. Matern Child Health J. 2017 Apr;21(4):903-14. doi: 10.1007/s10995-016-2192-9
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Brodtkorb TH, Bell M, Irving AH, Laramee P. The cost effectiveness of nalmefene for reduction of alcohol consumption in alcohol-dependent patients with high or very high drinking-risk levels from a UK societal perspective. CNS Drugs. 2016 Feb;30(2):163-77. doi: 10.1007/s40263-016-0310-2
Marcano-Belisario JS, Gupta AK, O'Donoghue J, Morrison C, Car J. Tablet computers for implementing NICE antenatal mental health guidelines: protocol of a feasibility study. BMJ Open. 2016 Jan 22;6(1):e009930. doi: 10.1136/bmjopen-2015-009930
Meyers J, Grebla R, Ajmera M, Davis K, Pawaskar M. Comorbidity burden in delayed and nondelayed ADHD diagnosis among commercially insured adults in the United States. Poster presented at the 28th Annual US Psychiatric and Mental Health Congress; September 10, 2015. San Diego, CA.
Laramee P, Brodtkorb TH, Rahnali N, Knight C, Barbosa C, Francois C, Toumi M, Daeppen JB, Rehm J. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model. BMJ Open. 2014 Sep 16;4(9). doi: 10.1136/bmjopen-2014-005376
Nagar SP, Patel A, Bali V, Aparasu RR. Prevalence and predictors of pediatric depression in the United States. Int J Pharm Sci Nanotech. 2014 Sep;7(3):91-7.
Candrilli SD, Karve SJ. Recent trends in hospitalizations related to post-traumatic stress disorder in the United States. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Kamat SA, Blanchette C, Wilson MR, Tangirala M, Earnshaw SR, Offord S, Gutierrez B, Eramo A, Baker RA. Healthcare cost savings associated with aripiprazole once-monthly (AOM) treatment among schizophrenia patients with psychiatric hospitalizations prior to AOM treatment initiation. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Karve S, Markowitz M, Fu DJ, Lindenmayer JP, Wang CC, Candrilli SD, Alphs L. Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder. Appl Health Econ Health Policy. 2014 Jun;12(3):335-46.
Von Schéele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):235-57. doi: 10.1586/14737167.2014.891443
Nagar SP, Mhatre S, Hatfeild MD, Aparasu RR. Patterns and predictors of antipsychotic usage among U.S. adults: a national co-morbidity survey replication study. Int J Pharm Sci Nanotech. 2014 Apr;7(2):52-68.
von Scheele B, Mauskopf J, Brodtkorb T, Ainsworth C, Galani Berardo C, Patel A. Relationship between modelling approach and reported outcomes: case studies of models for the treatment of schizophrenia. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A589.
Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L. Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization. BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246.
Wilson MR, Gutierrez B, Offord S, Zhao C, Beillat M, Eramo A, Earnshaw SR. Total healthcare cost-offset associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Poster presented at the US Psychiatric & Mental Health Congress; September 2013.
Panish J, Karve S, Candrilli SD, Dirani R. Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia. J Pharm Health Serv Res. 2013 Mar 1;4(1):29-39.
Hodgkins P, Setyawan J, Mitra D, Davis K, Quintero J, Fridman M, Shaw M, Harpin V. Management of adhd in children across europe: patient demographics, physician characteristics and treatment patterns. Eur J Pediatr. 2013 Feb 1;172(7):895-906.
Karve SJ, Panish JM, Dirani RG, Candrilli SD. Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Res Med. 2012 Nov 1;3(4):e183-94.
Markowitz M, Karve S, Fu D, Lindenmayer J, Wang C, Candrilli S, Alphs L. Assessing medication adherence and health care utilization and cost patterns among hospital discharged patients with schizoaffective disorder. Poster presented at the 2012 American Psychiatric Association Annual Meeting; May 2012.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012 Jan 1;15(1):55-64.
Stull DE, Houghton K. Examining variability in depression among pre-retirees: innovative analytic methods applied to observational data. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A301.
Karve S, Markowitz M, Panish J, Candrilli S, Cosmatos I, Alphs L. Assessing health care utilization and costs among hospital-discharged patients with schizophrenia. Poster presented at the 2011 US Psychiatric and Mental Health Congress; November 2011.
Markowitz M, Karve S, Panish J, Candrilli S, Cosmatos I, Alphs L. Evaluating antipsychotic adherence patterns among Medicaid-enrolled hospital-discharged patients with schizophrenia. Poster presented at the Psychiatric and Mental Health Congress; November 2011.
Karve SJ, Panish J, Dirani R, Candrilli SD. Annual health care costs for patients with schizophrenia experiencing multiple relapses after initiation of a second-generation oral antipsychotic. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011.
Panish J, Karve S, Candrilli S, Dirani R. Association between adherence and persistence with antipsychotics and outcomes among Medicaid patients with schizophrenia. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011.
Meyers J, Classi P, Wietecha L, Candrilli S. Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States. Child Adolesc Psychiatry Ment Health. 2010 Dec 1;4:31.
Lang K, Meyers JL, Korn JR, Lee S, Sikirica M, Crivera C, Dirani R, Menzin J. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010 Dec 1;61(12):1239-47.
Nagar S, Sherer JT, Chen H, Aparasu RR. Extent of functional impairment in children and adolescents with depression. Curr Med Res Opin. 2010 Sep;26(9):2057-64.
Sasane R, Mitra D, Hodgkins P, Davis KL. Childhood ADHD in Europe: a comparison of patient and physician profiles across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S616-7.
Mitra D, Sasane R, Hodgkins P, Davis KL. Management of ADHD among children in Europe: a comparison of practice patterns across countries. Poster presented at the 23rd ECNP Congress; August 2010. [abstract] Eur Neuropsychopharmacol. 2010 Aug; 20(Suppl. 3):S625-6.
Meyers J, Classi P, Wietecha LA, Candrilli S. The burden of attention-deficit/hyperactivity disorder (ADHD) on patients hospitalized with a primary diagnosis of oppositional defiant disorder (ODD). Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A182.
Classi P, Meyers J, Wietecha L, Candrilli S. Characteristics of hospitalizations for attention-deficit/hyperactivity disorder (adhd) among children and adolescents in the united states from 2000-2006. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A111.
Graham C, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating a cost-effectiveness analysis comparing olanzapine with ziprasidone in the treatment of schizophrenia. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May 1; 13(3):A113.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Zarkin GA, Cowell AJ, Hicks KA, Dunlap LJ, Belenko S, Mills MJ, Houser K, Keyes VS. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the International Society for the Study of Drug Policy Conference 2010; March 15, 2010. Santa Monica, CA. Previously presented at the Addiction Health Services Research Annual Conference.
Nagar S, Mehta S, Bhatara V, Aparasu R. Health care consequences of black-box warnings for antidepressants in the United States and Canada. Res Social Adm Pharm. 2010 Mar;6(1):78-84.
Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ, Belenko S, Houser K. The benefits and costs of prison-based substance abuse treatment. Presented at the Federal Consortium Addressing the Substance Abusing Offender; January 2010. Washington, DC.
Zarkin GA, Cowell AJ, Dunlap LJ, Hicks KA, Keyes VS, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the American Society of Criminology Annual Meeting; November 2009. Previously presented at the Addiction Health Services Research Annual conference.
Hicks KA, Zarkin GA, Dunlap LJ, Cowell AJ, Mills MJ, Keyes VS. A dynamic model for estimating the costs and benefits on prison-based substance abuse treatment. Poster presented at the American Society of Criminology Annual Meeting; November 2009.
Zarkin GA, Cowell AJ, Hicks KA, Dunlap LJ, Belenko S, Mills MJ. Benefits and costs of alternative substance abuse treatment programs for individuals in state prisons: results from a lifetime simulation model. Presented at the Addiction Health Services Research Annual conference; October 2009.
Jackel J, Davis KL, Candrilli SD. Trends in rates of pediatric bipolar disorder-related hospitalizations and related resource use in the United States. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 2009. Paris, France.